Scientists test 'Glowing' tracer to spot pancreatic tumors
NCT ID NCT06129422
Summary
This early-stage study tested a new imaging agent called NMK89 in patients with a specific type of pancreatic cancer. The main goal was to check if the agent is safe and to see how it travels and collects in the body using PET/CT scans. The study involved 10 patients to gather initial data on safety and imaging properties.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.